Twinrix Paediatric

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

hepatitis A virus (inactivated), hepatitis B surface antigen

Available from:

GlaxoSmithKline Biologicals S.A.

ATC code:

J07BC20

INN (International Name):

hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)

Therapeutic group:

Cepiva

Therapeutic area:

Immunization; Hepatitis B; Hepatitis A

Therapeutic indications:

Twinrix Pediatric je indiciran za uporabo pri neimunskih dojenčkih, otrocih in mladostnikih od enega leta do vključno 15 let, pri katerih obstaja tveganje za okužbo s hepatitisom A in hepatitisom B.

Product summary:

Revision: 23

Authorization status:

Pooblaščeni

Authorization date:

1997-02-10

Patient Information leaflet

                                16
EU/1/97/029/010 – pakiranje po 10 z 20 iglami
13.
ŠTEVILKA SERIJE
Številka serije:
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
17
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
1.
IME ZDRAVILA IN POT(I) UPORABE
Twinrix za otroke, suspenzija za injiciranje
HAB cepivo
i.m.
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP:
4.
ŠTEVILKA SERIJE
Številka erije:
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
1 odmerek (0,5 ml)
6.
DRUGI PODATKI
18
B. NAVODILO ZA UPORABO
19
NAVODILO ZA UPORABO
TWINRIX ZA OTROKE, SUSPENZIJA ZA INJICIRANJE V NAPOLNJENI INJEKCIJSKI
BRIZGI
Cepivo proti hepatitisu A, inaktivirano, in hepatitisu B,
rekombinantno (HAB), adsorbirano
PREDEN BOSTE PREJELI/BO VAŠ OTROK PREJEL CEPIVO NATANČNO PREBERITE
NAVODILO, KER VSEBUJE ZA VAS
POMEMBNE PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
farmacevtom.
-
Cepivo je bilo predpisano vam /vašemu otroku osebno in ga ne smete
dajati drugim.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali farmacevtom. Posvetujte
se tudi, če opazite katere koli neželene učinke, ki niso navedeni v
tem navodilu. Glejte
poglavje 4.
To navodilo za uporabo je bilo napisano ob predpostavki, da ga bere
oseba, ki bo prejela cepivo,
vendar pa se cepivo lahko da tudi mladostnikom in otrokom; v tem
primeru ga lahko preberete vi za
vašega otroka.
KAJ VSEBUJE NAVODILO
1.
Kaj je cepivo Twinrix za otroke in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden boste prejeli cepivo Twinrix za otroke
3.
Kako uporabljati cepivo Twinrix za otroke
4.
Možni neželeni učinki
5.
Shranjevanje cepiva Twinrix za otroke
6.
Vsebina pakiranja in dodatne inform
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Twinrix za otroke
,
suspenzija za injiciranje v napolnjeni injekcijski brizgi
Cepivo proti hepatitisu A, inaktivirano, in hepatitisu B,
rekombinantno (HAB), adsorbirano
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
1 odmerek (0,5 ml) vsebuje:
Virus hepatitisa A (inaktivirani)
1,2
360 ELISA enot
Površinski antigen virusa hepatitisa B
3,4
10 mikrogramov
1
Pridobljen na humanih diploidnih celicah (MRC-5)
2
Adsorbiran na hidratirani aluminijev hidroksid
0,025 miligrama Al
3+
3
Pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk
(
_Saccharomyces_
_cerevisiae_
)
4
Adsorbiran na aluminijev fosfat
0,2 miligrama Al
3+
Cepivo lahko vsebuje sledi neomicina, ki se uporablja v proizvodnem
procesu (glej poglavje 4.3).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Suspenzija za injiciranje
Motna bela suspenzija
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Cepivo Twinrix za otroke je indicirano za uporabo pri neimunih
dojenčkih, otrocih in mladostnikih,
starih od enega leta do vključno 15 let, pri katerih obstaja tveganje
za okužbo z virusom hepatitisa A
in virusom hepatitisa B.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_- _
Odmerek
_ _
Za dojenčke, otroke in mladostnike stare od 1 leta do vključno 15
let je priporočljiv odmerek 0,5 ml
(360 ELISA enot HA/10 mikrogramov HBsAg).
_- _
Osnovna shema cepljenja
_ _
Standardno osnovno cepljenje s cepivom Twinrix za otroke sestoji iz
treh odmerkov: prvi odmerek
apliciramo na izbrani dan cepljenja, drugi odmerek sledi 1 mesec po
prvem cepljenju in
tretji odmerek 6 mesecev po prvem cepljenju. Priporočeno shemo je
treba upoštevati. Za vse odmerke
osnovnega cepljenja je potrebno uporabiti isto cepivo.
_- _
Obnovitveni odmerek
_ _
3
V okoliščinah, ko je zaželen obnovitveni odmerek proti hepatitisu A
in/ali hepatitisu B, je mogoče
uporabiti monovalentno ali kombinirano cepivo. Varnost in imunogenost
cepiva Twinrix za otroke,
uporabljenega kot obnovitveni odmerek po 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-02-2024
Public Assessment Report Public Assessment Report Bulgarian 15-04-2008
Patient Information leaflet Patient Information leaflet Spanish 07-02-2024
Public Assessment Report Public Assessment Report Spanish 15-04-2008
Patient Information leaflet Patient Information leaflet Czech 07-02-2024
Public Assessment Report Public Assessment Report Czech 15-04-2008
Patient Information leaflet Patient Information leaflet Danish 07-02-2024
Public Assessment Report Public Assessment Report Danish 15-04-2008
Patient Information leaflet Patient Information leaflet German 07-02-2024
Public Assessment Report Public Assessment Report German 15-04-2008
Patient Information leaflet Patient Information leaflet Estonian 07-02-2024
Public Assessment Report Public Assessment Report Estonian 15-04-2008
Patient Information leaflet Patient Information leaflet Greek 07-02-2024
Public Assessment Report Public Assessment Report Greek 15-04-2008
Patient Information leaflet Patient Information leaflet English 07-02-2024
Public Assessment Report Public Assessment Report English 15-04-2008
Patient Information leaflet Patient Information leaflet French 07-02-2024
Public Assessment Report Public Assessment Report French 15-04-2008
Patient Information leaflet Patient Information leaflet Italian 07-02-2024
Public Assessment Report Public Assessment Report Italian 15-04-2008
Patient Information leaflet Patient Information leaflet Latvian 07-02-2024
Public Assessment Report Public Assessment Report Latvian 15-04-2008
Patient Information leaflet Patient Information leaflet Lithuanian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-02-2024
Public Assessment Report Public Assessment Report Lithuanian 15-04-2008
Patient Information leaflet Patient Information leaflet Hungarian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 07-02-2024
Public Assessment Report Public Assessment Report Hungarian 15-04-2008
Patient Information leaflet Patient Information leaflet Maltese 07-02-2024
Public Assessment Report Public Assessment Report Maltese 15-04-2008
Patient Information leaflet Patient Information leaflet Dutch 07-02-2024
Public Assessment Report Public Assessment Report Dutch 15-04-2008
Patient Information leaflet Patient Information leaflet Polish 07-02-2024
Public Assessment Report Public Assessment Report Polish 15-04-2008
Patient Information leaflet Patient Information leaflet Portuguese 07-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 07-02-2024
Public Assessment Report Public Assessment Report Portuguese 15-04-2008
Patient Information leaflet Patient Information leaflet Romanian 07-02-2024
Public Assessment Report Public Assessment Report Romanian 15-04-2008
Patient Information leaflet Patient Information leaflet Slovak 07-02-2024
Public Assessment Report Public Assessment Report Slovak 15-04-2008
Patient Information leaflet Patient Information leaflet Finnish 07-02-2024
Public Assessment Report Public Assessment Report Finnish 15-04-2008
Patient Information leaflet Patient Information leaflet Swedish 07-02-2024
Public Assessment Report Public Assessment Report Swedish 15-04-2008
Patient Information leaflet Patient Information leaflet Norwegian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 07-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 07-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 07-02-2024
Patient Information leaflet Patient Information leaflet Croatian 07-02-2024